Leucopenia and thrombocytopenia possibly associated with lamotrigine use in a patient

Epileptic Disorders

Volumn 7, Issue 1, 2005, Pages 33-35

  Ural, Ali Ugur ^a   Avcu, Ferit ^a   Gokcil, Zeki ^a   Nevruz, Oral ^a   Cetin, Turker ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Epilepsy; Lamotrigine; Leucopenia; Thrombocytopenia

Indexed keywords

LAMOTRIGINE;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; BLOOD TOXICITY; BONE MARROW BIOPSY; CASE REPORT; DISEASE COURSE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOCAL EPILEPSY; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOPENIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; ANTICONVULSANTS; ELECTROENCEPHALOGRAPHY; EPILEPSIES, PARTIAL; FEMALE; HUMANS; LEUKOCYTE COUNT; LEUKOPENIA; PLATELET COUNT; THROMBOCYTOPENIA; TRIAZINES;

EID: 14844299427     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Arzimanoglou A, Kulak I, Bidaut-Mazel C, Baldy-Moulinier M. Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy. Rev Neurol 2001; 157: 525-36.
2. Brodie MJ. Established anticonvulsants and treatment of refractory epilepsy. Lancet 1990; 336: 350-4.
3. Brodie MJ. Lamotrigine. Lancet 1992; 339: 1397-400.
4. de Camargo OA, Bode H. Agranulocytosis associated with lamotrigine. BMJ 1999; 318: 1179.
5. Fadul CE, Meyer LP, Jobst BC, Cornell CJ, Lewis LD. Agranulocytosis associated with lamotrigine in a patient with low-grade glioma. Epilepsia 2002; 43(2): 199-200.
6. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252-60.
7. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261-73.
8. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27: 490-7.
9. Levine SP. Miscellaneous causes of thrombocytopenia. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, eds. Wintrobe's Clinical Haematology. Philadelphia: Lippincott Willams, Wilkins, 2004; 1568.
10. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997; 38: 881-6.
11. Nicholson RJ, Kelly KP, Grant IS. Leucopenia associated with lamotrigine. BMJ 1995; 310: 504.
12. Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 1991; 32: S9-12.
13. Wong IC, Mawer GE, Sander JW. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. Epilepsia 2001; 42: 237-44.
14. Solvason HB. Agranulocytosis associated with lamotrigine. Am J Psychiatry 2000; 157: 1704.